查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1976591

造影剂市场：依药物类型、给药方式、应用、最终用户和通路划分－2026-2032年全球预测

Imaging Agents Market by Agent Type, Modality, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，成像剂市场价值将达到 107.6 亿美元，到 2026 年将成长到 114 亿美元，到 2032 年将达到 169.9 亿美元，复合年增长率为 6.73%。

主要市场统计数据
基准年 2025 107.6亿美元
预计年份：2026年 114亿美元
预测年份 2032 169.9亿美元
复合年增长率 (%) 6.73%

本导言阐述了不断变化的临床需求、技术融合以及法规环境的变化如何重塑全球造影剂生态系统。

诊断影像领域处于临床需求、技术进步和监管的交汇点，使其成为整个诊断流程创新的焦点。随着患者群体老化以及疾病检测模式向更早期、更精准的方法转变，製药、诊断和医疗服务领域的相关人员正在重新调整优先事项，以满足日益增长的安全性、特异性和工作流程效率方面的期望。分子成像技术的进步、超音波造影技术的超音波以及人们对放射性药物日益增长的兴趣，都在拓展诊断能力的同时，也为生产、分销和报销系统带来了新的复杂性。

分析美国于 2025 年实施的关税措施所带来的累积营运、采购和商业性影响以及供应链后果。

2025年实施的关税措施对造影剂供应链产生了多方面的影响，从组件采购到临床应用，各个环节都受到了波及。进口原料和成品关税的提高，使得依赖跨境供应链取得造影剂前驱物、放射性核种组件和专用包装材料的製造商的采购流程变得更加复杂。因此，各机构正在加速评估替代筹资策略，例如在地采购、多元化采购和策略储备，以降低供应中断的风险。

详细的細項分析解释了药物类型、成像方式、临床应用、最终用户和分销管道如何为每个相关人员创造不同的策略需求。

基于细分的分析揭示了每种造影剂、成像方式、临床应用、终端用户和分销模式所面临的不同机会和挑战。依药物类型分析显示，钆基造影剂、碘基造影剂、微气泡造影剂和放射性药物呈现不同的发展趋势。特别是放射性药物，又可进一步细分为PET和SPECT途径，需要专门的生产流程和监管。这种多样性要求针对每类药物独特的稳定性、操作特性和监管要求，制定量身订製的研发策略和生产投资。

区域洞察，提供对重点区域成像剂采用趋势的详细分析：揭示每个主要区域不同的法规结构、临床重点和基础设施能力如何影响成像剂的采用。

区域趋势正在显着影响美洲、欧洲、中东和非洲以及亚太地区的应用模式、监管方式和商业策略。在美洲，学术医疗中心和综合医疗保健系统的集中正在加速先进示踪剂和基于价值的影像方法的应用。同时，供应链韧性和报销谈判仍然是商业领域关注的核心议题。美洲的监管环境将严格的安全监测与针对特定适应症的加速临床导入途径结合，促使製造商调整证据产生以符合支付方的期望。

关键的竞争考察和策略性公司洞察，展示了製造、伙伴关係、分销和数位化整合的能力如何决定市场定位和差异化。

主要企业之间的竞争动态揭示了影响产业发展方向的若干策略重点。在放射化学、契约製造和法规遵循方面拥有深厚实力的公司，能够更好地满足市场对放射性药物的独特需求。同时，专注于传统造影剂的公司正透过改进配方和加强上市后监测来解决安全性和耐受性问题。策略伙伴关係和联盟模式日益普遍，推动了技术转移、合作临床开发和联合商业化等倡议，从而在控制资本密集度的同时，实现市场扩张。

我们为产业领导者提出的具体策略建议着重于加强供应链韧性、有针对性的研发、建立伙伴关係关係、与报销机制保持一致以及提供证据以推动永续成长。

产业领导者可以采取切实可行的策略行动，以应对不断变化的临床需求、日益复杂的监管以及供应链压力。首先，投资于具有韧性的价值链结构，包括区域性製造地和多元化的采购管道，可以降低受贸易政策波动和物流中断影响的风险。其次，研发工作应优先考虑安全性改进和临床差异化，从而确保符合监管要求，并透过改善患者预后和更清晰的价值提案来促进临床应用。

本研究采用一手和二手调查方法、专家检验和三角测量调查方法，以获得稳健而实用的市场见解。

本分析的调查方法结合了定性和定量方法，旨在提供可靠且实用的见解。初步调查包括对参与造影剂研发、生产和分销的临床负责人、监管专家、采购专员和商业高管进行结构化访谈。这些访谈提供了关于临床应用驱动因素、供应链挑战以及近期政策变化对商业影响的第一手观点。

总之，我们整合了技术创新、安全优先事项和供应链调整如何塑造造影剂价值链中所有相关人员的策略需求。

总之，造影剂产业的特点是技术快速发展、安全期望不断提高，以及供应链和政策趋势带来的不断变化的商业性压力。这些因素既给製造商、经销商、临床用户和支付方带来了挑战，也带来了机会。积极投资于更安全的化学成分、供应链韧性和整合诊断解决方案的机构，将更有能力满足临床医生的需求，并在竞争激烈的市场环境中脱颖而出。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：造影市场－依造影剂类型划分

  • 钆基造影剂
  • 碘造影剂
  • 微气泡造影剂
  • 放射性药物
    • PET造影剂
    • SPECT造影剂

第九章：造影剂市场：依影像方式划分

  • 电脑断层扫描
  • 磁振造影
  • 核子医学扫描术诊断
  • 超音波影像

第十章：造影剂市场：依应用领域划分

  • 心臟病学
  • 胃肠病学
  • 肌肉骨骼系统
  • 神经病学
  • 肿瘤学

第十一章造影剂市场：依最终用户划分

  • 学术研究机构
  • 门诊手术中心
  • 诊断检查室
  • 医院和诊断影像中心

第十二章：造影剂市场：依通路划分

  • 离线
  • 在线的

第十三章：造影市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章造影剂市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：造影剂市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国造影市场

第十七章：中国造影剂市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bayer AG
  • Bracco Imaging SpA
  • Cardinal Health, Inc.
  • Fujifilm Holdings Corporation
  • GE Healthcare
  • Guerbet SA
  • JB Chemicals & Pharmaceuticals Limited
  • Lantheus Holdings, Inc.
  • Livealth Biopharma
  • Mallinckrodt plc
  • Sagent Pharmaceuticals, Inc.
  • Scintica Instrumentation, Inc.
  • Siemens Healthineers AG
Product Code: MRR-69324464D0E7

The Imaging Agents Market was valued at USD 10.76 billion in 2025 and is projected to grow to USD 11.40 billion in 2026, with a CAGR of 6.73%, reaching USD 16.99 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.76 billion
Estimated Year [2026] USD 11.40 billion
Forecast Year [2032] USD 16.99 billion
CAGR (%) 6.73%

Introduction describing how evolving clinical demands, technological convergence, and regulatory dynamics are reshaping the global imaging agents ecosystem

The landscape of imaging agents sits at the intersection of clinical need, technological progress, and regulatory scrutiny, making it a focal point for innovation across diagnostic pathways. As patient populations age and disease detection paradigms shift toward earlier and more precise modalities, stakeholders across pharma, diagnostics, and healthcare delivery are recalibrating priorities to align with heightened expectations for safety, specificity, and workflow efficiency. Advancements in molecular imaging, improvements in ultrasound contrast technologies, and renewed interest in radiopharmaceuticals are converging to broaden diagnostic capabilities while also introducing new complexities in manufacturing, distribution, and reimbursement.

Across clinical specialties, imaging agents now play a central role not only in diagnosis but also in treatment planning and therapy monitoring. This expanded utility elevates demands on clinical validation, post-market surveillance, and interoperability with imaging platforms. In response, manufacturers and clinical partners are investing in evidence generation, standardized protocols, and digital tools that enhance image quantitation and reporting. Consequently, the ecosystem is evolving from a product-centric model toward integrated diagnostic solutions that combine agents, instrumentation, and analytics to deliver higher-value clinical outcomes.

The imaging agents sector is undergoing transformative shifts driven by technological innovation, heightened safety expectations, and a rapidly evolving regulatory environment. Molecular imaging advances are enabling greater target specificity, which in turn supports precision medicine approaches and more nuanced patient stratification. Concurrently, concerns about contrast safety-particularly around long-term retention and nephrotoxicity-have elevated the importance of agent chemistries and post-market data, prompting manufacturers to prioritize safer formulations and to invest in comparative clinical studies.

Technological convergence is another defining trend: hybrid imaging systems and enhanced image processing algorithms are increasing the diagnostic yield of established agents while stimulating demand for new tracers and contrast media optimized for quantitative imaging. In parallel, digital health tools, including AI-driven image analysis and cloud-based workflows, are changing how imaging agents are used in care pathways and research. These shifts are forcing traditional players to adopt cross-disciplinary strategies, forging partnerships with device manufacturers, software innovators, and clinical research organizations to maintain competitiveness and to deliver integrated solutions across clinical settings.

Analysis of the cumulative operational, procurement, and commercial effects stemming from the United States tariff measures enacted in 2025 and their supply chain consequences

The imposition of tariff measures in 2025 has produced a multifaceted impact on the imaging agents supply chain, creating ripple effects that extend from component sourcing to clinical deployment. Increased duties on imported raw materials and finished agents have elevated procurement complexity for manufacturers that rely on cross-border supply chains for contrast media precursors, radionuclide components, and specialized packaging materials. As a result, organizations have accelerated evaluations of alternative sourcing strategies, including local suppliers, multi-sourcing frameworks, and strategic stockpiling to mitigate disruption risks.

These trade policy changes have also influenced commercial dynamics. Healthcare providers and distributors are reassessing contract terms and pricing structures to manage margin pressures while maintaining service levels. Payers and hospital procurement teams are emphasizing cost-effectiveness and supply resiliency when selecting agents and vendors, prompting suppliers to demonstrate operational flexibility and value beyond unit pricing. In addition, regulatory and customs processes have required closer coordination, with firms enhancing compliance capabilities and logistics planning to reduce lead times and preserve continuity of care. Collectively, these adaptations underscore an industry-wide emphasis on supply chain robustness, collaborative contracting, and strategic operational agility.

In-depth segmentation insights explaining how agent types, imaging modalities, clinical applications, end users, and distribution channels create distinct strategic imperatives for stakeholders

Segmentation-based insights reveal differentiated opportunities and challenges across agent types, imaging modalities, clinical applications, end users, and distribution models. When analyzed by agent type, trends show distinct trajectories for gadolinium-based agents, iodinated contrast agents, microbubble agents, and radiopharmaceuticals, with radiopharmaceuticals further delineated into PET and SPECT pathways that demand specialized manufacturing and regulatory oversight. This diversity necessitates tailored R&D strategies and manufacturing investments to address the unique stability, handling, and regulatory profiles of each category.

From a modality perspective, computed tomography, magnetic resonance imaging, nuclear imaging, and ultrasound imaging each present different clinical and operational imperatives. Nuclear imaging requires close integration with PET and SPECT infrastructures and radiopharmacy networks, while ultrasound innovations encompass both two-dimensional and three-dimensional contrast agent applications that are more accessible in point-of-care environments. Clinical application segmentation highlights the varying agent requirements across cardiology, gastroenterology, musculoskeletal, neurology, and oncology, with oncology and neurology generally driving demand for higher specificity agents and more rigorous validation.

End-user segmentation illustrates how academic research institutes, ambulatory surgical centers, diagnostic laboratories, and hospitals and imaging centers adopt and deploy agents differently, with research institutions often prioritizing novel tracers and hospitals focusing on operational reliability and throughput. Distribution channel segmentation, spanning direct sales, distributors, and online retail, underscores the strategic importance of distribution partners; distributors themselves are differentiated into international and local distributors, each offering distinct reach, regulatory familiarity, and logistical capabilities that must be matched to product profiles and customer needs.

Key regional insights detailing how distinct regulatory frameworks, clinical priorities, and infrastructure capacities are influencing imaging agent adoption across major global regions

Regional dynamics shape adoption patterns, regulatory approaches, and commercial strategies in meaningful ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, a concentration of academic medical centers and integrated healthcare systems accelerates adoption of advanced tracers and value-based imaging approaches, while supply chain resilience and reimbursement negotiations remain central commercial concerns. The regulatory landscape in the Americas combines rigorous safety oversight with pathways for accelerated clinical adoption in select indications, prompting manufacturers to align evidence generation with payer expectations.

Europe, Middle East & Africa presents a heterogeneous set of regulatory regimes and healthcare delivery models, where centralized regulatory frameworks coexist with country-specific reimbursement and procurement mechanisms. This complexity rewards companies that invest in localized regulatory strategy and regionally tailored clinical programs. In the Asia-Pacific region, market dynamics are characterized by rapid infrastructure expansion, growing clinical research capacity, and an increasing emphasis on point-of-care imaging solutions. Local manufacturing capabilities and regional distribution partnerships are pivotal for scaling adoption, especially as clinical demand diversifies across oncology, cardiology, and neurology applications. Collectively, regional insights point to the importance of adaptive regulatory strategies, localized partnerships, and differentiated commercial approaches.

Key competitive and strategic company insights outlining how capabilities in manufacturing, partnerships, distribution, and digital integration are determining market positioning and differentiation

Competitive dynamics among leading organizations reveal several strategic priorities that are shaping the sector's trajectory. Companies with deep capabilities in radiochemistry, contract manufacturing, and regulatory affairs are positioned to capitalize on the specialized demands of radiopharmaceuticals, whereas firms focused on conventional contrast media are responding to safety and tolerability concerns through reformulation and enhanced post-market surveillance. Strategic partnerships and alliance models are increasingly common, enabling technology transfer, shared clinical development, and co-commercialization arrangements that extend market reach while managing capital intensity.

Manufacturers are also diversifying distribution strategies, balancing direct sales with distributor partnerships to optimize access across hospitals, diagnostic centers, and ambulatory settings. Concurrently, investment in quality systems, cold-chain logistics for temperature-sensitive agents, and compliance capabilities has become a competitive differentiator. In addition, a subset of actors is prioritizing the integration of digital tools and analytics to add demonstrable clinical value, improve imaging workflow efficiency, and support outcomes-based contracting discussions with payers. These trends indicate that success will favor organizations that combine technical excellence with operational flexibility and evidence-driven commercialization models.

Actionable strategic recommendations for industry leaders focused on supply chain resilience, targeted R&D, partnerships, reimbursement alignment, and evidence generation to drive sustainable growth

Industry leaders can pursue a practical set of strategic actions to navigate evolving clinical needs, regulatory complexity, and supply chain pressures. First, investing in resilient supply chain architectures, including regional manufacturing hubs and multi-sourced procurement, reduces vulnerability to trade policy shocks and logistical disruption. Second, aligning R&D priorities with safety enhancements and clinical differentiation helps address regulatory scrutiny and strengthens clinical adoption by delivering better patient outcomes and clearer value propositions.

Third, forming targeted alliances with device manufacturers, clinical research organizations, and digital health vendors accelerates the development of integrated diagnostic solutions that combine agents with imaging platforms and analytics. Fourth, cultivating payer engagement and designing evidence packages that demonstrate clinical utility and cost-effectiveness facilitate smoother reimbursement pathways. Fifth, optimizing distribution strategies by combining direct engagement in major accounts with partnerships for regional reach ensures operational efficiency and market coverage. Finally, enhancing post-market surveillance, real-world evidence generation, and clinician education programs builds trust with end users and supports long-term adoption across diverse clinical settings.

Research methodology describing the multi-source primary and secondary approaches, expert validation, and triangulation techniques used to derive robust, actionable market insights

The research methodology underpinning this analysis combined qualitative and quantitative approaches designed to deliver robust, actionable insights. Primary research included structured interviews with clinical leaders, regulatory experts, procurement specialists, and commercial executives involved in imaging agent development, manufacturing, and distribution. These interviews provided first-hand perspectives on clinical adoption drivers, supply chain challenges, and the commercial implications of recent policy changes.

Secondary research encompassed systematic review of regulatory filings, clinical trial registries, patent literature, and peer-reviewed publications to contextualize technological trends and safety considerations. In addition, supply chain mapping and logistics data were analyzed to understand the operational implications of tariff changes and to identify critical nodes of vulnerability. Findings were triangulated across data sources and validated through expert workshops, ensuring consistency and relevancy. Finally, methodological limitations and areas of uncertainty were documented, with transparency around data sources and assumptions to support informed decision-making by stakeholders.

Conclusion synthesizing how technological innovation, safety priorities, and supply chain adaptations will shape strategic imperatives for all stakeholders across the imaging agents value chain

In conclusion, the imaging agents landscape is characterized by rapid technological progress, intensifying safety expectations, and evolving commercial pressures driven by supply chain and policy dynamics. These forces are creating both challenges and opportunities for manufacturers, distributors, clinical users, and payers. Organizations that proactively invest in safer chemistries, supply chain resilience, and integrated diagnostic solutions are better positioned to meet clinician needs and to differentiate in increasingly competitive procurement environments.

Moving forward, success will hinge on cross-functional collaboration that links scientific innovation with pragmatic operational and commercial strategies. By prioritizing evidence generation, regulatory engagement, and strategic partnerships, stakeholders can accelerate clinical adoption while managing the operational complexities introduced by trade policy shifts and regional regulatory variance. Ultimately, a balanced focus on clinical value, operational robustness, and commercial adaptability will define which actors lead the next phase of evolution in imaging agents.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Imaging Agents Market, by Agent Type

  • 8.1. Gadolinium Based Agents
  • 8.2. Iodinated Contrast Agents
  • 8.3. Microbubble Agents
  • 8.4. Radiopharmaceuticals
    • 8.4.1. Pet Imaging Agents
    • 8.4.2. Spect Imaging Agents

9. Imaging Agents Market, by Modality

  • 9.1. Computed Tomography
  • 9.2. Magnetic Resonance Imaging
  • 9.3. Nuclear Imaging
  • 9.4. Ultrasound Imaging

10. Imaging Agents Market, by Application

  • 10.1. Cardiology
  • 10.2. Gastroenterology
  • 10.3. Musculoskeletal
  • 10.4. Neurology
  • 10.5. Oncology

11. Imaging Agents Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Ambulatory Surgical Centers
  • 11.3. Diagnostic Laboratories
  • 11.4. Hospitals And Imaging Centers

12. Imaging Agents Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Imaging Agents Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Imaging Agents Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Imaging Agents Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Imaging Agents Market

17. China Imaging Agents Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Bayer AG
  • 18.6. Bracco Imaging S.p.A.
  • 18.7. Cardinal Health, Inc.
  • 18.8. Fujifilm Holdings Corporation
  • 18.9. GE Healthcare
  • 18.10. Guerbet S.A.
  • 18.11. J. B. Chemicals & Pharmaceuticals Limited
  • 18.12. Lantheus Holdings, Inc.
  • 18.13. Livealth Biopharma
  • 18.14. Mallinckrodt plc
  • 18.15. Sagent Pharmaceuticals, Inc.
  • 18.16. Scintica Instrumentation, Inc.
  • 18.17. Siemens Healthineers AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMAGING AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMAGING AGENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMAGING AGENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMAGING AGENTS MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMAGING AGENTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMAGING AGENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMAGING AGENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES IMAGING AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA IMAGING AGENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMAGING AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMAGING AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMAGING AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMAGING AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMAGING AGENTS MARKET SIZE, BY IODINATED CONTRAST AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMAGING AGENTS MARKET SIZE, BY IODINATED CONTRAST AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMAGING AGENTS MARKET SIZE, BY IODINATED CONTRAST AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMAGING AGENTS MARKET SIZE, BY MICROBUBBLE AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMAGING AGENTS MARKET SIZE, BY MICROBUBBLE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMAGING AGENTS MARKET SIZE, BY MICROBUBBLE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMAGING AGENTS MARKET SIZE, BY PET IMAGING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMAGING AGENTS MARKET SIZE, BY PET IMAGING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMAGING AGENTS MARKET SIZE, BY PET IMAGING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMAGING AGENTS MARKET SIZE, BY SPECT IMAGING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMAGING AGENTS MARKET SIZE, BY SPECT IMAGING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMAGING AGENTS MARKET SIZE, BY SPECT IMAGING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMAGING AGENTS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMAGING AGENTS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMAGING AGENTS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMAGING AGENTS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMAGING AGENTS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMAGING AGENTS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMAGING AGENTS MARKET SIZE, BY NUCLEAR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMAGING AGENTS MARKET SIZE, BY NUCLEAR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMAGING AGENTS MARKET SIZE, BY NUCLEAR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMAGING AGENTS MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMAGING AGENTS MARKET SIZE, BY ULTRASOUND IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMAGING AGENTS MARKET SIZE, BY ULTRASOUND IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMAGING AGENTS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMAGING AGENTS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMAGING AGENTS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMAGING AGENTS MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMAGING AGENTS MARKET SIZE, BY GASTROENTEROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMAGING AGENTS MARKET SIZE, BY GASTROENTEROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMAGING AGENTS MARKET SIZE, BY MUSCULOSKELETAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMAGING AGENTS MARKET SIZE, BY MUSCULOSKELETAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMAGING AGENTS MARKET SIZE, BY MUSCULOSKELETAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMAGING AGENTS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMAGING AGENTS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMAGING AGENTS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMAGING AGENTS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMAGING AGENTS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMAGING AGENTS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMAGING AGENTS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMAGING AGENTS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMAGING AGENTS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMAGING AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMAGING AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMAGING AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMAGING AGENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMAGING AGENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMAGING AGENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMAGING AGENTS MARKET SIZE, BY HOSPITALS AND IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMAGING AGENTS MARKET SIZE, BY HOSPITALS AND IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMAGING AGENTS MARKET SIZE, BY HOSPITALS AND IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMAGING AGENTS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMAGING AGENTS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMAGING AGENTS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMAGING AGENTS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMAGING AGENTS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMAGING AGENTS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMAGING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS IMAGING AGENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA IMAGING AGENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL IMAGING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. GCC IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. GCC IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 139. GCC IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 140. GCC IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. GCC IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GCC IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. G7 IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. G7 IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. G7 IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 160. G7 IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. G7 IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. G7 IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. NATO IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NATO IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. NATO IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 167. NATO IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 168. NATO IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. NATO IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NATO IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES IMAGING AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA IMAGING AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)